Gottfries C G, Grind M, Lundström J, Alling C
Acta Pharmacol Toxicol (Copenh). 1986 Aug;59(2):94-102. doi: 10.1111/j.1600-0773.1986.tb00140.x.
The pharmacokinetics of zimeldine, a 5-HT reuptake blocker with antidepressive effects, was studied after a single oral dose and after multiple oral administration in 19 alcoholic males, 10 with and 9 without chronic liver damage. The average plasma concentration of zimeldine as assessed by the AUC values (area under the plasma concentration-time curve) was significantly higher in the chronically liver damaged patients than in the patients without chronic liver damage. The plasma half-life of zimeldine was also significantly longer in the chronically liver damaged patients. There were no differences in the obtained pharmacokinetic parameters between the patients having nonchronic liver damage and healthy control subjects. The pharmacokinetics of the active metabolite norzimeldine (resulting from N-demethylation of zimeldine) showed no differences between the two groups of alcoholics and the healthy controls. The IgA values were significantly correlated to both the AUC and plasma half-life of zimeldine. No other correlation between clinical chemistry parameters and pharmacokinetic parameters of zimeldine and norzimeldine were found.
齐美利定是一种具有抗抑郁作用的5-羟色胺再摄取阻滞剂，对19名男性酗酒者（其中10名有慢性肝损伤，9名无慢性肝损伤）进行了单剂量口服和多剂量口服后的药代动力学研究。根据AUC值（血浆浓度-时间曲线下面积）评估，慢性肝损伤患者的齐美利定平均血浆浓度显著高于无慢性肝损伤的患者。慢性肝损伤患者的齐美利定血浆半衰期也显著延长。非慢性肝损伤患者与健康对照受试者之间获得的药代动力学参数无差异。活性代谢物去甲齐美利定（由齐美利定的N-去甲基化产生）的药代动力学在两组酗酒者与健康对照之间未显示出差异。IgA值与齐美利定的AUC和血浆半衰期均显著相关。未发现临床化学参数与齐美利定和去甲齐美利定的药代动力学参数之间存在其他相关性。
